SLNO Overview

Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.

Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is110.50 USD with a low forecast of 75.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Soleno Therapeutics Inc revenue for the last quarter amounts to 91.73M USD, decreased

Soleno Therapeutics Inc. EPS for the last quarter amounts to 0.72 USD, decreased -156.69

Soleno Therapeutics Inc (SLNO) has 182 emplpoyees as of April 21 2026.

Today SLNO has the market capitalization of 2.72B USD.